EpiVacCorona (Russian: ЭпиВакКорона, tr. EpiVacCorona) is a peptide-based vaccine against COVID-19 developed by the Russian VECTOR Center of Virology.[2][3] The lack of protective effectiveness of EpiVacCorona, which is still in use in Russia, has been reported in scientific literature[4] and in the media.[5][6] The vaccine consists of three chemically synthesized peptides (short fragments of a viral spike protein) that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. A phase III clinical trial to show whether or not the vaccine can protect people against COVID-19 was launched in November 2020 with more than three thousand participants. The conclusions and results of the trial have not been made public.[7][8]
Some experts in the field have expressed concerns about the selection of peptides for use as vaccine antigens.[9][10] In addition, there are also serious concerns about the vaccine immunogenicity data, which have fueled independent civic research efforts[11][12][13] and criticism by some experts.[9] Current Time TV reported that "EpiVacCorona's reputation declined when vaccine trial participants sent an open letter to the Ministry of Health to flag 18 cases of COVID-19 infection among their group after vaccination with EpiVacCorona, and a lack of virus antibodies".[14]
^ ab"EpiVacCorona-N COVID-19 vaccine to be registered under Aurora-CoV brand name". Russian News Agency. 5 July 2021. Retrieved 6 July 2021.
^Cite error: The named reference :3 was invoked but never defined (see the help page).
^Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Danilenko ED, Imatdinov IR, Nechaeva EA, et al. (2021). "Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2". Annals of the Russian Academy of Medical Sciences. 76: 5–19. doi:10.15690/vramn1528. S2CID 234892966.
^Matveeva O, Ershov A (June 2022). "Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June-July 2021)". Vaccines. 10 (7): 984. doi:10.3390/vaccines10070984. PMC 9320764. PMID 35891148.
^"Studies suggest 'negative efficacy' for vaccine EpiVacCorona". THE BELL. 1 February 2022. Retrieved 3 May 2022.
^Ershov A (8 February 2022). "Worse than ineffective Two independent studies have confirmed that EpiVacCorona is a worthless vaccine — and it should be taken off the market". Meduza.
^Clinical trial number NCT04780035 for "Multicenter Double-blind Placebo-controlled Comparative Randomized Study of the Tolerability, Safety, Immunogenicity and Prophylactic Efficacy of the EpiVacCorona Peptide Antigen-based Vaccine for the Prevention of COVID-19, With the Participation of 3000 Volunteers Aged 18 Years and Above (Phase III-IV)" at ClinicalTrials.gov
^Tumakova I (21 August 2021). ""Мы хотим спасти людей от вакцины, если она неэффективна"". Novaya Gazeta. Retrieved 3 May 2022.
^ abDobrovidova O (6 April 2021). "Russia's COVID-19 defense may depend on mystery vaccine from former bioweapons lab—but does it work?". Science | AAAS. Retrieved 24 April 2021.
^Dobrovidova O (April 2021). "Latest Russian vaccine comes with a big dose of mystery". Science. 372 (6538): 116–117. Bibcode:2021Sci...372..116D. doi:10.1126/science.372.6538.116. PMID 33833104. S2CID 233191522.
^Reuters Staff (26 March 2021). "Volunteers break rank to raise doubts in trial of Russia's second COVID-19 vaccine". Reuters. Retrieved 23 April 2021.
^""ЭпиВакКорона" глазами участников клинических испытаний и ученых-биологов". Троицкий вариант — Наука (in Russian). 23 March 2021. Retrieved 23 April 2021.
^Ershov A (27 March 2021). "Sputnik V's ugly cousin Clinical results for Russia's EpiVacCorona vaccine are finally here, but developers published in an obscure local journal, raising questions and concerns". Meduza.
^"Russia's Domestic Manufacturers Struggle To Meet Spike In Demand For COVID-19 Vaccines". Current Time. 26 June 2021. Retrieved 3 May 2022.
EpiVacCorona (Russian: ЭпиВакКорона, tr. EpiVacCorona) is a peptide-based vaccine against COVID-19 developed by the Russian VECTOR Center of Virology...
CoronaVac, also known as the Sinovac COVID-19 vaccine, is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech...
vaccination is carried out under the Expanded Programme of Immunisation (EPI). Israel: BCG was given to all newborns between 1955 and 1982. Iran: Iran's...
GP2 has a lower affinity than E75. AE37 stimulates CD4+ lymphocytes. EpiVacCorona, a peptide-based vaccine against COVID-19. IC41 is a peptide vaccine...
from the original on 28 March 2019. Retrieved 12 March 2019. "Vaccines: Vac-Gen/Side Effects". www.cdc.gov. 12 July 2018. Archived from the original...
literally meaning "the study of what is upon the people", is derived from Greek epi 'upon, among', demos 'people, district', and logos 'study, word, discourse'...